Functional Dissection of the Free Fatty Acid-Binding Pocket in the SARS-CoV-2 Spike Protein
Lead Research Organisation:
University of Bristol
Department Name: Biochemistry
Abstract
Structural investigations on non-enveloped picornaviruses first identified a hydrophobic pocket in the virus particle serving as the binding site for host-derived lipids known as a 'pocket factor'. The pocket was shown to play a pivotal role in virus entry and presented an opportunity for antiviral drug targeting (1-3). We were the first to identify a hydrophobic pocket in the SARS-CoV-2 spike protein, conclusively establishing its interaction with linoleic acid (LA), a fatty acid humans cannot synthetise, as the pocket factor (4). Intriguingly, we could demonstrate that the pocket and LA-binding are strictly conserved in SARS-CoV, MERS-CoV, SARS-CoV-2 and all Variants of Concern (5), indicating a pivotal but yet elusive role of the pocket that is strictly maintained over 20+ years. Recent studies on other enveloped viruses, such as flaviviruses (6,7), alphaviruses (8), and influenza virus (9), unveiled more pocket factors, suggesting shared mechanisms whereby structural rearrangements in the virus particle, essential for infection, are regulated. However, the underlying functional mechanisms remain poorly understood. The combined use of state-of-the-art structural biology, protein engineering, biophysics, computational modelling and virological approaches have placed us at the forefront of the field in defining how the binding of a pocket factor to an enveloped virus can affect spike protein stability, structural rearrangements, virus entry and replication (4,5,10-14).
The pocket in SARS-CoV-2 spike we discovered binds specifically LA, with nanomolar affinity (4). We showed that LA-binding induces a locked spike conformation incompatible with binding to human host cell receptor ACE2, thus inhibiting viral infection. Further, LA-treatment of human cells already infected with SARS-CoV-2 suppresses viral replication and results in deformed virions (5). Here, we aim to elucidate the functional importance of the pocket, and the molecular mechanisms how LA-binding (i) impacts the structural integrity and dynamics of spike and the virion (ii) alters viral infection, and (iii) regulates viral replication. To obtain these fundamental new insights, we will use computational, biophysical and structural approaches to design and characterize SARS-CoV-2 ancestral and variant spike protein mutants that no longer bind LA or any other fatty acid. We will compare wild-type and mutant spike proteins, dissecting the impact of LA-binding to the pocket on spike architecture, dynamics and ACE2-binding. By reverse genetics, we will prepare virus comprising the spike mutants identified. We will elucidate the effect of LA-treatment on viral infection, replication in cells and cell-to-cell spread with mutant virus we prepare, and analyse mutant virion morphology and spike conformation in situ using state-of-the-art imaging approaches.
Our proposal aims at fundamental new understanding to advance the frontiers of bioscience discovery, in line with the BBSRC long-term research and innovation priority 'Understanding the Rules of Life'. Leveraging our interdisciplinary research strategy and utilizing the SARS-CoV-2 interaction with LA as a model, we aim to address essential gaps in understanding the role pocket factors play in the viral lifecycle and explore the evolutionary advantages specific viruses may gain from these interactions, towards a paradigm for pocket factor function.
The pocket in SARS-CoV-2 spike we discovered binds specifically LA, with nanomolar affinity (4). We showed that LA-binding induces a locked spike conformation incompatible with binding to human host cell receptor ACE2, thus inhibiting viral infection. Further, LA-treatment of human cells already infected with SARS-CoV-2 suppresses viral replication and results in deformed virions (5). Here, we aim to elucidate the functional importance of the pocket, and the molecular mechanisms how LA-binding (i) impacts the structural integrity and dynamics of spike and the virion (ii) alters viral infection, and (iii) regulates viral replication. To obtain these fundamental new insights, we will use computational, biophysical and structural approaches to design and characterize SARS-CoV-2 ancestral and variant spike protein mutants that no longer bind LA or any other fatty acid. We will compare wild-type and mutant spike proteins, dissecting the impact of LA-binding to the pocket on spike architecture, dynamics and ACE2-binding. By reverse genetics, we will prepare virus comprising the spike mutants identified. We will elucidate the effect of LA-treatment on viral infection, replication in cells and cell-to-cell spread with mutant virus we prepare, and analyse mutant virion morphology and spike conformation in situ using state-of-the-art imaging approaches.
Our proposal aims at fundamental new understanding to advance the frontiers of bioscience discovery, in line with the BBSRC long-term research and innovation priority 'Understanding the Rules of Life'. Leveraging our interdisciplinary research strategy and utilizing the SARS-CoV-2 interaction with LA as a model, we aim to address essential gaps in understanding the role pocket factors play in the viral lifecycle and explore the evolutionary advantages specific viruses may gain from these interactions, towards a paradigm for pocket factor function.
Publications
Oliveira A
(2025)
pH-induced structural changes in SARS-CoV-2 spike variants
Oliveira A
(2025)
Allosteric modulation by the fatty acid site in the glycosylated SARS-CoV-2 spike
in eLife
| Description | Appointed Monitor EC Horizon 2020, FET open programme (2021-2025) |
| Geographic Reach | Europe |
| Policy Influence Type | Contribution to a national consultation/review |
| Description | Appointed member of Oversight committee for 1.2 GHz NMR in the UK (2024-today) |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| Description | Chair of the reviewer panel of the NCCR Antiresist |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| URL | https://www.nccr-antiresist.ch/ |
| Description | Co-Chair of the review panel of the NCCR 'Bio-inspired Materials' |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| URL | https://www.bioinspired-materials.ch/en/ |
| Description | Member of the evaluation panel for the 6th NCCR series of SNSF (National Centre of Competence in Research), Switzerland |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| URL | https://www.news.admin.ch/en/newnsb/JEYzIEzRw1QFKXIpHWlxC |
| Description | Wittenstein Foundation, Reviewer for Joint professorship University of Hohenheim & Frauenhofer Institute, Germany |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Contribution to a national consultation/review |
| Title | Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein |
| Description | When we analysed the atomic structure of the SARS-CoV-2 Spike glycoprotein, we discovered a previously unknown hydrophobic pocket within in the protein. To our surprise, inside of the pocket, we found a small molecule. It turned out that this small molecule was linoleic acid. With the help of Andrew Davidson and his team, we could show that binding of linoleic acid to the spike protein blocks virus replication. Thus, unexpectedly, we discovered not only a druggable pocket in the SARS-COV-2 Spike protein, but also a potential drug, linoleic acid, in the pocket, which could be used as antiviral to protect us for infection by the virus. We are now entering pre-clinical trials testing Linoleic acid as an antiviral against SARS-CoV-2. |
| Type Of Material | Model of mechanisms or symptoms - human |
| Year Produced | 2020 |
| Provided To Others? | Yes |
| Impact | Similar fatty acid binding pockets are found frequently in other proteins which are implicated in diseases. Blocking such a pocket with a drug, typically a small molecule, can inhibit the function of such proteins and provide a cure. In our study, the small molecule is linoleic acid - it binds to the pocket and distorts the SARS-Cov-2 Spike protein, dialling down the infectivity of the virus. Our data suggests that linoleic acid could be a drug that could be used as a potent antiviral to protect us from infection. In the future, based on our discovery, new drugs could be developed that bind even better to the pocket to suppress viral infectivity entirely and eliminate Covid-19. We have raised the money for pre-clinical tests to further pursue this idea. We envision a Linoleic Acid-nasal spray that could be used early in SARS-CoV-2 infection to block viral respiration in the respiratory tract. We are currently preparing for clinical phases I and II. In parallel, medical doctors in USA have already used Linoleic Acid using a nebulizer with remarkable success. This is possible in the USA in emergency cases (compassionate care), but not in the UK. We therefore have to go through preclinical tests and clinical trial phases to establish Linoleic Acid as an antiviral drug against Covid-19. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3746712 [Symptom Duration Shortened by Early Initiation of Nebulized Isomerized Linoleic Acid (LA) for Outpatient Treatment of COVID-19.] https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3733231 [Case Study Using Nebulized Isomerized Linoleic Acid (LA) for Outpatient Treatment of Symptomatic COVID-19.] |
| URL | https://science.sciencemag.org/content/370/6517/725.full |
| Title | Pathogen-sugar interactions revealed by universal saturation transfer analysis |
| Description | Supporting data for the "Pathogen-sugar interactions revealed by universal saturation transfer analysis" manuscript. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2022 |
| Provided To Others? | Yes |
| URL | https://zenodo.org/record/6299883 |
| Title | Structural insights in cell-type specific evolution of intra-host diversity by SARS-CoV-2 |
| Description | Structural datasets and coordinates generated during the current study have been deposited in the Electron Microscopy Data Bank (EMDB) under accession numbers EMD-12818 (C3 structure) and EMD-12842 (C1 structure) and in the Protein Data Bank (PDB) under accession numbers: 7OD3 (C3 structure) and 7ODL (C1 structure). |
| Type Of Material | Database/Collection of data |
| Year Produced | 2022 |
| Provided To Others? | Yes |
| Impact | The article has an altmetric score of 175, has been tweeted >150 times up to now and led to 16 new and views outlets. The structure has been accessed >50 times already. |
| URL | http://www.emdataresource.org/EMD-12818 |
| Title | Structures and atomic model of SARS-CoV-2 spike protein in the open and locked/LA-bound conformation |
| Description | We deposited the cryo-EM structure of the SARS-CoV-2 spike protein in its open and closed/locked conformation in the Electron Microscopy Data Bank (EMDB) under accession numbers EMD-11145 (C3 closed conformation), EMD-11144 (C1 closed conformation), and EMD-11146 (open conformation) and in the Protein Data Bank (PDB) under accession numbers: 6ZB5 (C3 closed conformation) and 6ZB4 (C1 closed conformation). |
| Type Of Material | Database/Collection of data |
| Year Produced | 2020 |
| Provided To Others? | Yes |
| Impact | The structure and model have been downloaded more than 100 times already. We have used the atomic model to search for other potential antivirals that could bind to the free fatty acid binding pocket in the spike protein and block the spike protein in a non-infectious conformation. We have published our results in Die Angewandte 2021. The altrimetric score of our Science paper describing the structure is 1574 which puts it in the top 5% of all research outputs scored by Altmetric. |
| URL | https://science.sciencemag.org/content/370/6517/725.full |
| Title | Structures of SARS-CoV spike glycoprotein in the open and closed conformation |
| Description | Datasets generated during this study have been deposited in the Electron Microscopy Data Bank (EMDB) under accession numbers EMD-14718 (C1 locked conformation), EMD-14717 (C3 locked conformation), and EMD-14724 (RBD-up open conformation) and in the PDB under accession numbers 7ZH2 (C1 locked conformation), 7ZH1 (C3 locked conformation), and 7ZH5 (RBD-up open conformation). |
| Type Of Material | Database/Collection of data |
| Year Produced | 2022 |
| Provided To Others? | Yes |
| Impact | structure highlights the fact that the free fatty acid binding pocket in the spike protein of pathogenic b-coronavirus is conserved since 20 years (since SARS-CoV-2). |
| URL | https://www.science.org/doi/10.1126/sciadv.adc9179?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&r... |
| Title | Structures of an anti-Covid vaccine nanoparticle and of anti-spike nanobody binding and inhibiting infection by SARS-CoV-2 |
| Description | The datasets have been deposited in the Electron Microscopy Data Bank (EMDB) under accession numbers EMD-16512 (ADDoCoV), EMD-16522 (ADDoCoV-ADAH11), and in the Protein Data Bank (PDB) under accession number PBD ID 8C9N (ADDoCoV). |
| Type Of Material | Database/Collection of data |
| Year Produced | 2023 |
| Provided To Others? | Yes |
| Impact | Designed a vaccine nanoparticle for SARS-CoV-2 and generated neutralising nanobodies against SARS-CoV-2 spike protein |
| URL | https://academic.oup.com/abt/article/6/4/277/7320073 |
| Description | Collaboration with Prof Adrian Mulholland and Dr Sofia Oliveira for molecular dynamics simulations of SARS-CoV-2 spike protein |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have solved the cryo-EM structure of the SARS-CoV-2 spike protein and discovered a free fatty acid binding pocket. We immediately made our atomic model available to Adrian Mulholland and Deborah Shoemark for molecular dynamics simulations |
| Collaborator Contribution | Adrian Mulholland and Deborah Shoemark performed molecular dynamics simulations to understand Linoleic acid binding to the spike protein. Furthermore, they performed molecular modelling to see if they could identify other ligands (other fatty acids ) binding to the hydrophobic pocket in spike protein. |
| Impact | The molecular dynamics simulations were published in Science in September 2020, together with the cryo-EM structure. The molecular modelling study was published in Die Angewandte in 2021. |
| Start Year | 2020 |
| Description | Collaboration with Prof Andrew Davidson on SARS-CoV-2 virology |
| Organisation | University of Bristol |
| Department | School of Cellular and Molecular Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Functional Dissection of the Free Fatty Acid-Binding Pocket in the SARS-CoV-2 Spike Protein |
| Collaborator Contribution | Reverse Genetics of SARS-CoV-2, Evolution experiments, Characterisation of viral infection and replication |
| Impact | Publications: https://www.biorxiv.org/content/10.1101/2025.11.17.688702v1.full.pdf, doi: 10.7554/eLife.97313, doi: 10.1093/abt/tbad024, doi: 10.1093/jmcb/mjad021, doi: 10.1126/sciadv.adc9179, doi: 10.1038/s41467-021-27881-6, doi: 10.1016/j.csbj.2021.12.011, doi: 10.1002/ange.202181362, doi: 10.1002/anie.202015639, doi: 10.1126/science.abd3255. Patents: 2021: Methods and material compositions for pan-coronavirus antivirals (Patent number PCT/EP2021/066723) Interviews: 13.05.2024: Research presentation and discussion at 'Pint of Science', Bristol 23.03.2024: Research presentation to pupils and parents at the Offer Holder Day, University of Bristol 11.03.2022: Interview for International Women Day, Oracle for Research with Alison Derbenwick Miller (VP, Oracle for Research): In scientific research, success has many mothers (oracle.com) 02.03.2022 University of Bristol Offer Holder Visit Day presentation to parents and pupils 09.03.2021: Interview for International Women Day, Bristol Post: International Women's Day: the 87 most influential women in Bristol right now - Bristol Live (bristolpost.co.uk) 08.03.2021: International Women's Day 2021, Univ. of Bristol, Interview: Tackling COVID-19: Prof Christiane Berger-Schaffitzel - Bristol Uni Women 02/2021: Interview in the Bristol Magazine Online: The Pride of Bristol - The Bristol Magazine Online 25.02.2021: UKRI Festival of Tomorrow, invited presentation 27.01.2021: Interview, BBC Points West and Breakfast news. 01/2021: SARS-CoV-2 Feature, Nature Struct. Mol. Biol. 22/02/2021: Bristol University Alumni Magazine, Interview: Spotlight on COVID-19 research: Professors Imre Berger and Christiane Schaffitzel - Alumni Blog (bristol.ac.uk) 17.12.2020: Univ. of Bristol Staff meeting, Covid-19 research presentation 02.12.2020: Univ. of Bristol Development Board, Covid-19 research presentation 18.10.2020: Burst Student Radio Bristol 12/10/2020: Named 'Coolest Person in Bristol 2020' by Bristol Post: The Bristol Cool List 2020: The city's 41 coolest people right now - Bristol Live (bristolpost.co.uk) 28.11.2020: FUTURES2020 public festival funded by the European Commission, open to the general public. 'Understanding Covid-19' presentation. Invited talk. |
| Start Year | 2020 |
| Description | Collaboration with Prof Imre Berger on SARS-CoV-2 spike protein biochemistry, biophysics and structural biology |
| Organisation | University of Bristol |
| Department | School of Biochemistry Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We solved the cryo-EM structure of the SARS-CoV-2 spike glycoprotein and performed biophysical characterisations of ligand binding (antibodies, ACE2 receptor, fatty acids). |
| Collaborator Contribution | Design of expression constructs, expression, purification of proteins, biophysical characterisation, structural biology (crystallography), expertise in model building |
| Impact | This collaboration involves biochemistry, molecular biology, structural biology and biophysics. We have published more than 60 publications together. |
| Description | Collaboration with Prof Joachim Spatz on mass spectrometry and biophysics of SARS-CoV-2 Spike protein |
| Organisation | Max Planck Society |
| Department | Max Planck Institute for Medical Research |
| Country | Germany |
| Sector | Charity/Non Profit |
| PI Contribution | We produced the SARS-CoV-2 Spike protein using MultiBac insect cell expression. We solved the cryo-EM structure at 2.8A resolution and identified a free fatty acid ligand, which we suspected to be Linoleic Acid. |
| Collaborator Contribution | Oskar Staufer in Joachim Spatz's laboratory used LC-ESI TOF to determine the mass of the ligand , which was compatible with Linoleic Acid. He further used LC-MS/MS to prove that the ligand is Linoleic Acid |
| Impact | This collaboration is multidisciplinary as we are using biophysics, structural biology and cell biology to study the Linoleic Acid binding pocket in the SARS-CoV-2 spike protein. The discovery of the SARS-CoV-2 binding pocket was published in Science in September 2020. |
| Start Year | 2020 |
| Description | Collaboration with Prof Paul Verkade on SARS-CoV-2 spike protein structural biology using cryo-tomography |
| Organisation | University of Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We express and purify proteins, biochemically and biophysically characterise them and use single particle cryo-EM for structural analysis. |
| Collaborator Contribution | The Verkade team uses correlative light and electron microscopy to characterise the SARS-CoV-2 virus and spike protein in situ , i.e. in cells |
| Impact | The collaboration involves molecular biology, biochemistry, biophoyics and structural biology and cell biology. We have published a Science Advances paper in 2023 and currently work on the structural analysis of SARS-CoV-2 Spike protein variants using cryo-tomography. |
| Start Year | 2021 |
| Title | Methods and material compositions for pan-coronavirus antivirals (Patent number PCT/EP2021/066723) |
| Description | We discovered a druggable pocket in the SARS-CoV-2 spike protein. Similar pockets are found frequently in other proteins which are implicated in diseases. Blocking such a pocket with a drug, typically a small molecule, can inhibit the function of such proteins and provide a cure. In our study, the small molecule is linoleic acid - it binds to the pocket and distorts the Spike protein, dialling down the infectivity of the virus. Our data suggests that linoleic acid could be already a drug that could be used as a potent antiviral to protect us from SARS-CoV-2 infection. |
| IP Reference | not available yet |
| Protection | Patent application published |
| Year Protection Granted | 2021 |
| Licensed | Commercial In Confidence |
| Impact | We have been contacted by leading experts from academia and pharma with concrete suggestions how to translate our finding into a treatment against Covid-19. With these experts we have now put together a realistic and fully costed clinical trial plan to translate our discovery to the bedside as soon as possible. We have secured the funding required for pre-clinical tests and work to raise the funding for clinical trial phase 1 and 2. |
| Title | Using Linoleic Acid (LA) for Treatment of COVID-19. |
| Description | Inspired by our Science paper, two medical doctors in USA have used Linoleic Acid already as an antiviral drug against Covid-19. This is possible in emergencies (compassionate care) in USA, but not in UK. We require pre-clinical tests (currently done) and clinical trials (hopefully starting in 3 months in Bristol). https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3746712 [Symptom Duration Shortened by Early Initiation of Nebulized Isomerized Linoleic Acid (LA) for Outpatient Treatment of COVID-19.] https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3733231 [Case Study Using Nebulized Isomerized Linoleic Acid (LA) for Outpatient Treatment of Symptomatic COVID-19.] |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2021 |
| Development Status | Closed |
| Impact | not applicable yet |
| URL | https://science.sciencemag.org/content/370/6517/725 |
| Company Name | Halo Therapeutics |
| Description | Halo Therapeutics develops antivirals to treat a range of Coronavirus diseases. |
| Year Established | 2020 |
| Impact | Funding has been raised from private investors for preclinical studies. |
| Website | http://halo-therapeutics.com |
| Description | British-Swiss Synbio Summit, London, UK |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Discussed international collaboration and the future impact of AI on research and development. |
| Year(s) Of Engagement Activity | 2025 |
| Description | Seminar, host pathogen interaction symposium, IBS Grenoble, France |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | Presented our SARS-CoV-2 research to ca 80 participants. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Talk at School of Cellular Medicine and Microbiology, Univ. of Bristol |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | Presented our SARS-CoV-2 spike protein structure and ongoing work in the laboratory. |
| Year(s) Of Engagement Activity | 2025 |
| Description | UK Japan Engineering Biology Workshop, London UK, networking panelist |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Participated in a panel discussion abut the importance of research collaborations and team work in the presence of ca 120 participants |
| Year(s) Of Engagement Activity | 2025 |
| Description | University of Leicester, Biochemistry Seminar |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | Presented ongoing and past research in the laboratory to ca 40 PhD students, Postdocs and PIs. |
| Year(s) Of Engagement Activity | 2026 |
